abemaciclib
Sermonix, Henlius Ink China-Based Licensing Deal for Lasofoxifene in ESR1-Mutant Breast Cancer
Henlius will develop the endocrine therapy and fund the Phase III ELAINE-3 trial in China, while Sermonix retains the global rights elsewhere.
The Swiss firm reported solid sales growth across its oncology portfolio during the first quarter of 2023 as overall sales increased 3 percent.
FDA Expands Early-Stage Breast Cancer Indication for Eli Lilly's Verzenio in Adjuvant Setting
The drug can now be given with endocrine therapy to patients with HR-positive HER2-negative breast cancer that's node-positive and at high risk of recurrence.
Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor
Results from the Phase III MONARCH 3 trial further filled out the picture of how different CDK4/6 inhibitors perform long term, though questions remain.
Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues
The Swiss drugmaker's overall revenue fell 1 percent in Q2, but sales for the CDK4/6 inhibitor climbed 37 percent thanks to an overall survival advantage versus competitors.